NASDAQ: ABVC

ABVC BIOPHARMA, INC.

CIK 0001173313 · SIC 2834 · Pharmaceutical Preparations

Micro Revenue $296K Assets $20M as of Nov 15, 2026

The biotechnology industry focuses on developing breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important business sector in the world’s economies and is vital to human health. Companies engaged in biotechnology… About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (CNXC 10-Q) is open in full — no account needed.

424B4 Filed Nov 13, 2026

Summary not yet generated.

424B4 Filed Nov 13, 2026

Summary not yet generated.

Partner

Trade ABVC commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

424B4 Filed Nov 13, 2026

Summary not yet generated.

424B4 Filed Nov 13, 2026

Summary not yet generated.

10-Q Filed Nov 10, 2026 · Period ending Sep 30, 2026

Summary not yet generated.

8-K Filed Nov 2, 2026 · Period ending Oct 30, 2026

Summary not yet generated.

8-K Filed Aug 27, 2026 · Period ending Aug 27, 2026

Summary not yet generated.

10-Q Filed Aug 12, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Aug 4, 2026 · Period ending Aug 3, 2026

Summary not yet generated.

10-Q/A Filed Mar 3, 2026 · Period ending Sep 30, 2025

Summary not yet generated.

10-K Filed Mar 3, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-K Filed Apr 15, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

424B5 Filed Aug 7, 2024

Summary not yet generated.

424B5 Filed Aug 7, 2024

Summary not yet generated.

S-1 Filed Jun 21, 2024

Summary not yet generated.

S-1/A Filed Mar 22, 2024

Summary not yet generated.

10-K/A Filed Mar 15, 2024 · Period ending Dec 31, 2023

Summary not yet generated.

Latest financial statements

From 10-Q filed Nov 10, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Description Three months ended September 30 2026 Three months ended September 30, 2025 Nine months ended September 30 2026 Nine months ended September 30, 2025
(Restated)
Revenues - - - -
Cost of revenues - - - -
Gross loss - - - -
Operating expenses
Selling, general and administrative expenses 376,946 798,253 1,632,722 2,103,718
Research and development expenses 18,040 29,890 73,847 92,027
Stock-based compensation 845,607 1,136,217 1,886,022 2,756,603
Total operating expenses 1,240,593 1,964,360 3,592,591 4,952,348
Loss from operations (1,240,593) (1,964,360) (3,592,591) (4,952,348)
Other income (expense)
Interest income 2,384 47,287 6,832 85,497
Interest expense (43,649) (30,959) (135,349) (383,339)
Operating sublease income 27,622 29,680 56,829 53,680
Gain (loss) on foreign exchange (361) (112,553) (40,139) 13,683
Loss on investment in equity securities (6,816) (54,235) (62,998) (150,029)
Other (expenses) income (128,719) 2,194 (123,134) (3,486)
Total other expenses (149,539) (118,586) (297,959) (383,994)
Loss before provision for income tax (1,390,132) (2,082,946) (3,890,550) (5,336,342)
Provision for income tax expense - 527 - 24,154
Net loss (1,390,132) (2,083,473) (3,890,550) (5,360,496)
Net loss attributable to noncontrolling interests (2,539,432) (41,010) (2,742,674) (218,936)
Net loss attributed to ABVC shareholders 1,149,300 (2,042,463) (1,147,876) (5,141,560)
Foreign currency translation adjustment 16,609 3,236 27,200 41,383
Comprehensive loss 1,165,909 (2,039,227) (1,120,676) (5,100,177)
Net loss per share:
Basic and diluted 0.04 (0.09) (0.04) (0.28)
Weighted average number of common shares outstanding:
Basic and diluted 26,656,942 23,256,590 26,059,207 18,567,480

Condensed Consolidated Balance Sheets (Unaudited)

Description September 30, 2026 December 31, 2025
(revised*)
ASSETS
Current Assets
Cash and cash equivalents 11,294 681,480
Restricted cash - 645,505
Due from related parties 934,111 1,523,388
Convertible notes receivable related parties 29,930 -
Short-term investments 55,160 64,354
Prepaid expense and other current assets 373,889 346,616
Total Current Assets 1,404,384 3,261,343
Property and equipment, net 12,825,164 12,835,409
Operating lease right-of-use assets 1,658,963 1,913,278
Long-term investments 2,484,137 1,878,465
Prepayment for long-term investments 1,124,842 1,124,842
Prepayment for asset acquisition 691,900 691,900
Other non-current assets 106,682 116,966
Total Assets 20,296,072 21,822,203
LIABILITIES AND EQUITY
Current Liabilities
Short-term bank and other loans 30,000 755,512
Accrued expenses and other current liabilities 4,533,972 4,161,629
Contract liabilities 12,600 12,600
Operating lease liabilities 338,794 317,557
Due to related parties 1,478,178 865,704
Taxes payable - 11,964
Convertible notes payable third parties 559,010 559,010
Convertible notes payable related parties 240,000 240,000
Total Current Liabilities 7,192,554 6,923,976
Tenant security deposit 18,667 -
Operating lease liability non-current 1,343,207 1,600,747
Total Liabilities 8,554,428 8,524,723
COMMITMENTS AND CONTINGENCIES
Equity
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding - -
Common stock, $0.001 par value, 100,000,000 authorized, 26,841,266 and 25,053,193 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively 26,841 25,053
Stock to be issued 105,000 359,000
Additional paid-in capital 98,567,984 96,008,258
Accumulated deficit (77,254,088) (76,858,361)
Accumulated other comprehensive income 514,802 487,602
Treasury stock (8,909,691) (8,909,691)
Total Stockholders’ equity 13,050,848 11,111,861
Noncontrolling interest (1,309,204) 2,185,619
Total Equity 11,741,644 13,297,480
Total Liabilities and Equity 20,296,072 21,822,203

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Nine months ended September 30 2026 Nine months ended September 30 2025
2026
Cash flows from operating activities
Net loss (3,890,550) (5,360,496)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation 19,205 19,539
Stock-based compensation 1,886,022 2,756,603
Other non-cash expenses 123,666 343,242
Loss on investment in equity securities 62,998 150,029
Loss on short-term investment 8,689 -
Amortization of right-of-use asset 250,866 271,252
Changes in operating assets and liabilities:
Inventories - (11,460)
Prepaid expenses and other current assets (17,877) (76,067)
Due from related parties (38,404) (205,299)
Accrued expenses and other current liabilities 247,343 (10,384)
Tenant security deposit 18,667 (4,865)
Taxes payables (11,889) 6,170
Operating lease liabilities (236,303) (276,981)
Net cash used in operating activities (1,577,567) (2,398,717)
Cash flows from investing activities
Loan to related parties (193,752) (1,319,352)
Payment for Long-term investment (668,403) -
Payment for convertible notes receivable- related party (32,000) -
Land acquisition transaction costs - (5,421)
Repayment from related parties 816,249 145,637
Net cash used in investing activities (77,906) (1,179,136)
Cash flows from financing activities
Proceeds from private offerings 319,492 2,777,120
Proceeds from exercise of warrants 102,000 991,366
Repayment of short-term loans (739,201) (90,281)
Proceeds from convertible notes payable - 9,010
Due to related parties, net 610,434 -
Repayment of convertible notes payable - (277,284)
Proceeds from convertible notes payable to related parties - 150,000
Net cash provided by financing activities 292,725 3,559,931
Effect of exchange rate changes on cash and cash equivalents and restricted cash 47,057 8,018
Net decrease in cash and cash equivalents and restricted cash (1,315,691) (9,904)
Cash, cash equivalents and restricted cash
Beginning 1,326,985 863,815
Ending 11,294 853,911
Cash, cash equivalents and restricted cash
Cash and cash equivalents 11,294 192,068
Restricted cash - 661,843
Cash, cash equivalents and restricted cash at end of the year 11,294 853,911
Supplemental disclosure of cash flows
Cash paid during the year for:
Interest expense paid 4,579 22,078
Income taxes (refunded) paid (1,239) 2,013
Non-cash financing and investing activities
Acquiring control of the land - 7,670,000
Issuance of common stock for conversion of debt - 463,847
Conversion of convertible note due from related parties to equity investment - 563,819
Common stock and warrants issued for acquisition of land - 4,156,461
Loan assumed in land acquisition - 500,000

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About ABVC BIOPHARMA, INC.

Source: Item 1 (Business) from the 10-K filed March 3, 2026. Description as filed by the company with the SEC.

ITEM 1. DESCRIPTION OF BUSINESS

Industry Overview

The biotechnology industry focuses on developing
breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important
business sector in the world’s economies and is vital to human health. Companies engaged in biotechnology generally require
large amounts of capital investment for their research & development activities. Developing and commercializing a new drug or medical
device may take up to tens of years. ABVC (“we” or the “Company”) is an early-stage biotechnology company with
a pipeline of seven new drugs and one medical device under development, all of which are licensed from related parties of the Company.

Our Mission

We devote our resources to building a sophisticated
biotech company and becoming a pioneer in the biopharmaceutical industry. Dr. Uttam Patil, our Chief Executive Officer, and Dr. Tsung-Shann
Jiang, the founder and majority shareholder of the Company, understand the challenges and opportunities of the biotech industry and intend
to provide therapeutic solutions to significant unmet medical needs and to improve health and quality of human life by developing innovative
botanical drugs to treat central nervous system (“CNS”) and oncology/ hematology diseases.

Business

As of the date of this Report, the Company’s
revenue has come from outlicensing our intellectual properties and providing CDMO services. The Company focuses on developing a product
pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region.
Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company’s scientists and other specialists
known to the Company to identify drugs or medical devices that it believes demonstrate efficacy and safety based on the Company’s
internal qualifications. Once a drug or medical device is shown to be a good candidate for further development and ultimately commercialization,
ABVC licenses the drug or medical device from the original researchers and introduces the drug or medical device clinical trial plan to
highly respected principal investigators in the United States, Australia and Taiwan. In almost all cases, ABVC has found that research
institutions in each country are eager to work with the Company to move forward with Phase II clinical trials.

Read full description ↓

Institutions that have or are now conducting phase
II clinical trials in partnership with ABVC include:

● Drug:
ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F.
Schatzberg, MD, Stanford University Medical Center, Cheng-Ta Li, MD, Ph.D – Taipei Veterans General Hospital

● Drug:
ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed. Principal Investigators: Keith McBurnett,
Ph.D. and Linda Pfiffner, Ph.D., University of California San Francisco (UCSF), School of Medicine. Phase II, Part 2 clinical study
sites include UCSF and 5 locations in Taiwan. The Principal Investigators are Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D., University
of California San Francisco (UCSF), School of Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D.
Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D.; Kaohsiung Chang Gung Memorial Hospital; Ton-Ping Su, M.D., Cheng Hsin General
Hospital; Cheng-Ta Li, M.D., Taipei Veterans General Hospital. Phase II, Part 2 began in the 1st quarter of 2022 at the 5
Taiwan sites. The UCSF site joined the study in the 2nd quarter of 2023. The subjects enrolled in the study has reached the
number for interim analysis in December 2023, and the clinical study report was sent to the FDA.

● Drug:
ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. – Cedars
Sinai Medical Center (CSMC). The Company is trying to determine whether they can move into Phase II directly, since there is sufficient
safety data from the MDD trial.

● Medical
Device: ABV-1701, Vitargus® in vitrectomy surgery, Phase II Study has been initiated in Australia and Thailand, Principal Investigator:
Duangnate Rojanaporn, M.D., Ramathibodi Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital of the two Thailand Sites and Professor/Dr.
Matthew Simunovic, Sydney Eye Hospital; Dr. Elvis Ojaimi, East Melbourne Eye Group & East Melbourne Retina. The Phase II study
started in the 2nd quarter of 2023, and the company is working on improvements to the Vitargus Product through the new batch of investigational
product.

3

The following trials are expected to begin in
the third quarter of 2026:

●
Drug: ABV-1519, Non-Small Cell Lung Cancer treatment, Phase I/II Study in Taiwan, Principal Investigator: Dr. Yung-Hung Luo, M.D., Taipei Veterans General Hospital (TVGH)

●
Drug: ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, Principal Investigator: Andrew E. Hendifar, MD – Cedars Sinai Medical Center (CSMC)

Upon completing a Phase II trial, ABVC will seek
a partner, typically a large pharmaceutical company, to complete a Phase III study and commercialize the drug or medical device upon approval
by the US FDA, Taiwan TFDA and other country regulatory authorities.

GMP Manufacturing

ABVC owns a certified GMP manufacturing facility
through BioKey that is qualified to deliver small quantities of drugs for use by its clients in clinical trials from Phase I to Phase
III. The GMP facility can manufacture direct API or blend fill-in capsules, manual and automated encapsulation, wet granulation or tray
drying, tablet compression, coating, and packaging solid dosage forms for ANDA and IND submission.

The BioKey facility comprises a GMP suite, product development area,
analytical laboratory, food processing area, caged GMP storage area receiving area and two warehouses. The facility was remodeled in
December 2008 and received its first drug manufacturing license in June 2009. ABVC’s current drug manufacturing license allows it
to manufacture drug products under IND for human clinical trials until the expiration of the license on December 2, 2024. We are working
on upgrading the facility and equipment, so the renewal of licenses is in progress.

In 2022, BioKey began manufacturing a dietary
supplement based on the maitake mushroom. The mushrooms, supplied by Shogun Maitake Canada, Co. Ltd., are grown in a controlled
temperature and humid environment free of pesticides and chemicals. Initially, sales of the new supplement in the US and Canada will be
targeted to high-end grocery stores worldwide via online distribution. While many mushroom-based supplements are currently available to
customers, BioKey believes its new line has a significant competitive advantage since the purity and consistency of the mushrooms themselves
exceeds any maitake mushrooms currently available, and the extraction process employed by BioKey delivers a particularly strong dose.
The maitake mushroom is rich in bioactive polysaccharides, especially beta-glucans. These polysaccharides have well-documented immune-protecting
and antitumor properties. BioKey has developed both a tablet and a liquid version of the supplement. GMP manufacturing of bulk quantities
of Maitake mushroom tablets and Maitake mushroom drinks was completed in 2 and 1 batches, respectively, for commercial launches in Taiwan
and Canada in 2022.

Beta-glucans in maitake mushrooms have been shown
to reduce cholesterol, resulting in improved artery functionality and overall better cardiovascular health, lowering the risk of heart
disease. Further, studies have shown that the beta-glucans in maitake mushrooms strengthen the immune system. In a trial of postmenopausal
breast cancer patients, oral administration of a maitake extract was shown to have immunomodulatory effects. In a different Memorial Sloan
Kettering Cancer Center trial, maitake extracts enhanced neutrophil and monocyte function in patients with myelodysplastic syndrome. It
boosts the production of lymphokines (protein mediators) and interleukins (secreted proteins), improving immune response. Further,
clinical trials have shown beta-glucans to lower blood glucose levels, helping to activate insulin receptors while reducing insulin resistance
in diabetes management.

On December 6, 2021, BioKey entered into a three-year distribution
agreement with Define Biotech Co. Ltd. This Taiwan-based pharmaceutical marketing company focuses on selling drugs, dietary supplements,
and medical products in the Asia-Pacific region. The agreement grants Define Biotech the exclusive right to distribute this new dietary
supplement in China and Taiwan in exchange for the commitment to purchase $3.0 million of the new product over three years. The parties
have mutually agreed that the contract auto renewed for another 2 years, through December 6, 2026.

NASDAQ Listing

On July 10, 2024, the Company received a notification
letter from the listing qualifications staff (the “Staff”) of Nasdaq notifying the Company that the minimum bid price per
share for its common shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets
the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The notification received has
no immediate effect on the listing of the Company’s common stock on Nasdaq. Under the Nasdaq Listing Rules, the Company had until
January 6, 2025, to regain compliance.

On January 9, 2025, the Company received a notification
from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share,
as outlined in the Rule.

On May 13, 2025, the Company received a notification
letter (the “Notification Letter”) from Nasdaq notifying the Company that the Staff has determined that the Company has met
the Bid Requirement and therefore the matter is closed. Accordingly, no reverse stock split is necessary at this time.

4

On April 24, 2025, the Company received a letter
from the Staff informing the Company that, as reported in its Annual Report on Form 10-K for the year ended December 31, 2024, because
its stockholders’ equity was $723,959, as of April 23, 2025, it did not meet the alternatives of market value of listed securities
or net income from continuing operations, and it no longer complied with Listing Rule 5550(b)(1) (“Rule 5550”). The Company
had 45 calendar days to submit a plan to the Staff to regain compliance. If the plan wass accepted, the Company was eligible to receive
an extension of up to 180 calendar days from the date of the letter, or until October 21, 2025, to evidence compliance.

On April 30, 2025, the Company reported that it
received a letter from the Staff informing it that, as reported in its Annual Report on Form 10-K for the year ended December 31, 2024,
because its stockholders’ equity was $723,959, as of April 23, 2025, the Company did not meet the alternatives of market value of
listed securities or net income from continuing operations, and it no longer complied with Listing Rule 5550.

On May 5, 2025, the Company received a notification
letter from Nasdaq notifying the Company that the Staff has determined that based on the Company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2025, which evidenced stockholders’ equity of $7,956,295, the Company complies with Listing Rule
5550 and the matter is closed.

Our Pipeline

I. Central
Nervous System

1. ABV-1504
to treat Major Depressive Disorder (“MDD”)

We are developing and researching ABV-1504,
a botanical reuptake inhibitor that targets norepinephrine. Before clinical trials, we conducted radioligand-binding assay tests on ABV-1504.
Radioligand-binding assays are used to characterize the binding effects of a drug to its target receptor. In the case of ABV-1504, the
receptors of radioligand-binding assays are norepinephrine, dopamine, and serotonin. The radioligand-binding assay test on norepinephrine
was conducted from May 3 to May 8, 2007, and the radioligand-binding assay test on dopamine and serotonin was administered from November
26 to December 5, 2007. The result of the radioligand-binding assay to norepinephrine of ABV-1504was 2.102 μg/ml of IC50, which indicated
ABV-1504’s high inhibitory efficiency on norepinephrine. The results of the radioligand-binding assay to dopamine and serotonin
were not as good as those for norepinephrine, which indicated lower inhibitory efficiency. Because research has shown that norepinephrine
inhibitors can alleviate the level of depression, our research team saw ABV-1504’s potential to treat depression and decided to
commence the clinical trial process of ABV-1504.

In 2013, ABVC completed the Phase I
clinical trial of ABV-1504. The primary objective of the Phase I study was to assess the safety profile of ABV-1504. The safety endpoint
was assessed based on the results of physical examinations, vital signs, laboratory data, electrocardiograms (“ECG”), Columbia-Suicide
Severity Rating Scale evaluation, and several adverse events during the study period. We began recruiting healthy people as subjects for
the Phase I trial in Taiwan on October 30, 2012. We screened 85 healthy volunteers at the Taipei Veterans General Hospital for the Phase
I trial and enrolled 30 people as trial subjects. We divided the subjects into four cohort groups and administered ABV-1504oral capsules
of 380 mg, 1140 mg, 2280 mg, and 3800 mg to the subjects in each cohort group, respectively. BioLite visited the first subject for the
first time on November 13, 2012, and the last subject for the last time on July 5, 2013. During the said period, no subject had a severe
adverse event nor discontinued the trial due to any adverse events. ABVC did not observe any clinically significant findings in physical
examinations, vital signs, electrocardiogram, laboratory measurements, and C-SSRS throughout the treatment period. However, ABVC observed
the following mild adverse events: two subjects with flatulence and one subject with constipation in the single-dose 380mg cohort of seven
subjects; one subject with somnolence and one subject with stomatitis ulcer in the single-dose 2,280 mg cohort. Comparatively, two subjects
with somnolence and one subject with stomatitis ulcer were observed in the placebo group of seven subjects. ABVC did not observe any suicidal
ideation or behavior throughout the trial period. ABV-1504’s Phase I clinical trial results reflected that the oral administration
of ABV-1504 to healthy volunteers was safe and well-tolerated at the dose levels of 380 mg to 3,800 mg.

ABVC received an IND approval to proceed
with the Phase II clinical trial of ABV-1504 from the F.D.A. in March 2014 and an IND approval for its Phase II trial from the Taiwan
F.D.A. in June 2014. For the Phase II trial, BioLite administered oral capsules to 72 MDD patients (the trial subjects) in a randomized,
double-blind study with a placebo control group to assess ABV-1504’s efficacy and safety profile, primarily under the Montgomery-Åsberg
Depression Rating Scale (“MADRS”). ABVC via BioLite began recruiting Phase II subjects in March 2015 at the following study
sites; Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, Taipei City Hospital-Songde Branch, Tri-Service General
Hospital, Wan Fang Hospital and started recruiting MDD patients at Stanford Depression Research Clinic. The first five sites are in Taiwan,
and the last one is in the United States. The primary endpoint of the Phase II trial is to see changes in the subjects’ MADRS total
scores from the baseline scores of the placebo subjects within the first six weeks. The secondary objectives of the Phase II trial are
to evaluate the efficacy and safety profile of ABV-1504 on other rating scales with secondary endpoints of (i) demonstrating changes in
MADRS total scores from baseline scores within the second to seventh weeks and (ii) showing changes in the total scores on Hamilton Rating
Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Depression and Somatic Symptoms Scale (DSSS), Clinical Global
Impression Scale (CGI) from the baseline scores in the second, fourth, sixth and seventh week. ABVC plans to measure the percentages of
partial responders (subjects with a 25% to 50% decrease in total MADRS scores from the baseline score) and responders (subjects with a
50% or more decrease in total MADRS scores from the baseline score) by the second, fourth, sixth and seventh week. Additionally, ABVC
intends to monitor the subjects’ performance following the Safety Assessments and Columbia-Suicide Severity Rating Scale from the
screening stage to each subject’s last visit as well as to analyze the differences in the mean changes of MADRS, HAM-D-17, HAM-A,
DSSS, CGI, and Columbia-Suicide Severity Rating Scale scores of the subjects administered with ABV-1504 and the placebo group in the second,
fourth, sixth and seventh week.

5

On May 23, 2019, the Company announced
the Phase II clinical study results of ABV-1504. The clinical study results showed that PDC-1421, the active pharmaceutical ingredient
of ABV-1504, met the pre-specified primary endpoint of the Phase II clinical trial and significantly improved the symptoms of MDD. The
Phase II clinical study was a randomized, double-blind, placebo-controlled, multi-center trial, in which sixty (60) adult patients with
confirmed moderate to severe MDD were treated with PDC-1421 in either low dose (380 mg) or high dose (2 x 380 mg) compared with placebo
administration, three times a day for six weeks. PDC-1421 high dose (2 x 380 mg) met the pre-specified primary endpoint by demonstrating
a highly significant 13.2-point reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score by Intention-To-Treat
(ITT) analysis, averaged over the 6-week treatment period (overall treatment effect) from baseline, as compared to the 9.2-point reduction
of the placebo group. By Per-Protocol (PP) analysis, PDC-1421 showed a dose-dependent efficacy toward MDD in which a high dose (2 x 380
mg) gave a 13.4-point reduction in MADRS total score from baseline and a low dose (380 mg) gave a 10.4-point reduction as compared to
an 8.6-point in the placebo group. Based on the trial results above, the Company has decided to use the high-dose formula for ABV-1504’s
Phase III clinical trial.

2. ABV-1505
to treat Attention Deficit Hyperactivity Disorder (“ADHD”)

We developed the ADHD indication from
the same API of ABV-1504. Also, ABV-1505 shares a pharmaceutical mechanism of action similar to ABV-1504 in that ABV-1505 can potentially
increase the level of norepinephrine in the human nervous system by inhibiting its reabsorption. Because of ABV-1505’s sufficient
similarity with ABV-1504, in January 2016, the FDA approved our IND application to conduct ABV-1505’s Phase II clinical trial based
on its preclinical research and the Phase I trial results of ABV-1504.

For the ADHD Phase II trial, ABVC plans
to recruit a maximum of 105 ADHD patients as trial subjects in the United States and Taiwan, to whom ABVC intends to administer ABV-1505
oral capsules. ABVC has designed a randomized, double-blind dose escalation study with a placebo-controlled group to assess the efficacy
and safety profile of ABV-1505, primarily against the ADHD Rating Scale-IV (“ADHD-RS-IV”). The primary endpoint of the Phase
II trial is a 40% or higher improvement in the ADHD-RS-IV from the respective baseline scores within up to eight weeks. The secondary
objective is to determine the efficacy and safety profile of ABV-1505 on other rating scales with secondary endpoints of (i) improvements
of the total ADHD symptom scores from the respective baseline scores on the Conners’ Adult ADHD Rating Scale-Self Report: Short
Version (“CAARS-S:S”) 18-Item for a treatment period of eight weeks at maximum; and (ii) achievement of scores of two or lower
on both the Clinical Global Impression-ADHD- Severity (“CGI-ADHD-S”) and Clinical Global Impression-ADHD-Improvement (“CGI-ADHD-I”)
from the subjects’ respective baseline scores. The University of California San Francisco (“UCSF”) initiated the Phase
II, Part 1 clinical trial entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit
Hyperactivity Disorder (ADHD). Part I on January 14, 2020. The Part 1 trial is a single-center, open-label, dose-escalation evaluation
with two dosage levels in six subjects. Six subjects were initially evaluated for safety and efficacy assessments at low-dose (1 capsule
of PDC-1421, three times a day (TID)) for 28 days. A safety checkpoint was evaluated on day 28 for entering the high-dose (2 capsules
TID). The subjects who passed the checkpoint were evaluated for safety and efficacy assessments at high-dose (2 capsules of PDC-1421 TID)
for 28 days. On July 15, 2020, the last patient visit (LPLV) marked the final step toward the completion of the ABV-1505 Phase II Part
I clinical trial for the treatment of adult ADHD. On October 24, 2020, a full clinical study report (CSR) of ABV-1505 Phase II Part I
clinical trial was issued. The study results showed that the PDC-1421 Capsule was safe, well tolerated, and efficacious during its treatment
and follow-up with six adult patients. For the primary endpoints, the percentages of improvement in ADHD-RS-IV score from baseline to
8 weeks of treatment were 83.3% (N=5) in the ITT population and 80.0% (N=4) in the PP population. Both low and high doses of PDC-1421
Capsules met the primary end points by passing the required 40% population in ADHD-RS-IV test scores. Overall, the results from this study,
which demonstrate the therapeutic value of PDC-1421, support further Phase II Part II clinical development of ABV-1505 for the treatment
of adult ADHD.

The Phase II Part II study with its
clinical protocol entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit
Hyperactivity Disorder (ADHD), Part II” is a randomized, double-blind, placebo-controlled, parallel three-groups with a maximum
99 subjects to be enrolled. This study was started at five Taiwan medical centers beginning in April 2022. The University of California,
San Francisco site was initiated in the 2nd quarter of 2023. The subjects enrolled in the study has reached the number
for interim analysis (69 subjects) in 2023 December, and the interim analysis of the study is now in progress with the clinic study report
submitted to the FDA.

6

3. ABV-1601
to treat Depression in Cancer Patients

We developed a treatment for depression
in cancer patients from the same active pharmaceutical ingredients as ABV-1504. ABV-1601 shares similar pharmaceutical mechanisms of action
as ABV-1504 in that ABV-1601 can potentially increase the level of norepinephrine in the human nervous system by inhibiting its reabsorption.
Due to ABV-1601’s similarity with ABV-1504, the FDA approved our ABV-1601-001 clinical protocol under the same IND as ABV-1504 (IND
112567) in December 2018.

For the Phase II trial of ABV-1601,
ABVC plans to recruit a maximum number of 54 cancer patients with depression, to whom ABVC intends to administer ABV-1601 oral capsules.
ABVC is engaging the Principal Investigator at Cedars-Sinai Medical Center in the U.S. which designed a randomized, double-blind dose
escalation study with a comparator-controlled group to assess the efficacy and safety profile of ABV-1601, primarily against Montgomery-Åsberg
Depression Rating Scale (MADRS) total score. The primary endpoint of the Phase II trial is a change in MADRS, Hospital Anxiety and Depression
Scale (HADS), subscales (HADS-A and HADS-D), and Clinical Global Impression Scale (CGI) total scores from baseline in patients taking
PDC-1421 compared to the comparator. As of the date of this report, Part I of Phase II clinical protocol, which is an open trial, has
been approved by the Cedars-Sinai Medical Center IRB Committee. This study will be initiated around the end of 2026.

II. Oncology

1. ABV-1702
to treat Myelodysplastic Syndrome (“MDS”)

ABVC started the preparation for ABV-1702’s
Phase II clinical trials after receiving its IND approval from the FDA in July 2016. ABVC plans to recruit fifty-two subjects in the United
States diagnosed with either IPSS int-1, IPSS int-2 high-risk MDS, or CMML and may take azacitidine as part of the subjects’ prescription.
Azacitidine is an FDA-approved drug used to treat MDS. ABVC intends to administer ABV-1702 in the oral liquid form along with azacitidine.
The Phase II trial is divided into two parts, where Part 1 is to determine the safety and recommended dose level (“RDL”) of
ABV-1702 in combination with azacitidine and Part 2 is to determine whether ABV-1702 under the established RDL reduces bactericidal and
fungicidal infection in the subjects’ respiratory systems. The primary endpoint of the Part 1 Phase II trial is to assess the safety
and RDL profile of ABV-1702 administered with azacitidine by measuring ABV-1702’s prohibited toxicity. The secondary endpoints of
Phase II Part 1 are to determine the safety, time-to-first infection after the first dose (Day 1) of the first azacitidine treatment cycle,
reduction in treatment requirements and duration of infections, enhancement of immune responses, improvements of response rates, progression,
and survival rates of the subjects under such ABV-1702 - azacitidine combination treatment. The primary endpoint of Part 2 of Phase II
is to determine whether ABV-1702 under the established RDL reduces bactericidal and fungicidal infection risks in the subjects’
respiratory systems in combination with azacitidine as compared to the control group with incidence of infections and incidence/frequency
of inpatient hospitalization due to infections. The secondary endpoints of Part 2 of Phase II are to determine the safety, time-to-first
infection after the first dose (Day 1) of the first azacitidine treatment cycle, reduction in required dosage and duration of infection,
enhancement of immune responses, improvement of response rate, progression, and survival rates of the subjects under the trial conditions.
In April 2016, BioLite submitted a letter to the FDA responding to its queries with additional information about the proposed Phase II
trial.

The Company expects to begin Phase
II clinical trials of ABV-1702 in the fourth quarter of 2026 and is actively looking for qualified principal investigators and an appropriate
site for the study; therefore, the timing cannot be guaranteed.

7

2. ABV-1703
to treat Pancreatic Cancer

ABVC developed a new indication for
pancreatic cancer from maitake extract, named ABV-1703, and licensed it to Rgene to prepare its IND application with the FDA. On August
25, 2017, the FDA approved ABV-1703’s Phase II trial. According to the ABVC-Rgene Co-development Agreement, ABVC is responsible
for coordinating and conducting the clinical trials of ABV-1703 globally and Rgene is responsible for preparing the related FDA applications.
As of the date of this report, we are engaging Cedars-Sinai Medical Center in the U.S. to conduct the Phase II clinical trial and plan
to initiate the Phase II trial in 2026. We plan to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after we commence
the clinical trials in the United States.

3. ABV-
1501 Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (“TNBC”)

●
ABV- 1501 is developed from BLI-1401-2, whose active pharmaceutical ingredient is Yukiguni Maitake Extract 404. Memorial Sloan Kettering Cancer Center (“MSKCC”) conducted the Phase I clinical trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom), which is very similar to Yukiguni Maitake Extract 404. The Phase I trial focused on the immunological effects of Grifola frondosa extract on breast cancer patients. The results of the Phase I trial showed that oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.

●
Our ABV-1501 Investigational New Drug (“IND”) application to the US FDA for the Phase II clinical trials referencing the MSKCC maitake research resulted in a Phase II IND approval in March of 2016 by the U.S. FDA.

●
The collaboration with BHK to file a clinical trial application to the Taiwan FDA (“TFDA”) for conducting this combination therapy trial in Taiwan was temporarily put on hold due to the lack of funding.

Our Collaborative Agreements

I. ABV-1701
Vitreous Substitute for Vitrectomy and Collaboration Agreement with BioFirst

On July 24, 2017, BriVision, one of
our wholly-owned subsidiaries entered into a collaboration agreement (the “BioFirst Agreement”) with BioFirst, under which
BioFirst granted BriVision the global license to co-develop BFC-1401 Vitreous Substitute for Vitrectomy (“BFC-1401”) for medical
purposes. BioFirst is a related party to the Company because BioFirst and YuanGene Corporation (“YuanGene”), the Company’s
controlling shareholder, are under common control, both controlled by the controlling beneficiary shareholder of YuanGene.

According to the BioFirst Agreement,
we will co-develop and commercialize BFC-1401 or ABV-1701 with BioFirst. We must pay BioFirst $3.0 million (the “Total Payment”)
in cash or common stock of BriVision on or before September 30, 2018 in two installments. An upfront payment of $300,000, representing
10% of the Total Payment due under the Collaboration Agreement, was to be paid upon executing the BioFirst Agreement. BriVision will receive
50% of the future net licensing income or net sales profit when ABV-1701 is sublicensed or commercialized. On June 30, 2019, the Company
and BioFirst entered into a Stock Purchase Agreement (the “Purchase Agreement”), according to which the Company will issue
428,571 shares of the Company’s common stock to BioFirst in consideration for $3.0 million owed by the Company to BioFirst in connection
with the BioFirst Collaborative Agreement. For more information about the BioFirst Agreement and Purchase Agreement, please refer to the
current reports on Form 8-K filed on July 24, 2017 and July 12, 2019.

On November 7, 2016, the Phase I clinical
trial application prepared and submitted by BioFirst was approved by the Human Research Ethics Committee, Australia (“HREC”).
On November 14, 2016, it was approved by the Therapeutic Goods Administration, Australia (“TGA”).

We successfully finished the Phase
I clinical trial of ABV-1701 at Sydney Retina Clinic and Day Surgery, a clinic in Sydney, Australia. This was the only site for this Phase
I clinical trial. The trial started on November 17, 2016, and was completed with positive results in July 2018. The Protocol Title is
“A Phase I, single-center, safety and tolerability study of Vitargus in the treatment of Retinal Detachment.”

8

The primary endpoint of this Phase
I clinical trial was to evaluate the safety and tolerability of a single intravitreal dose of Vitargus in patients as a vitreous substitute
during vitrectomy surgery for retinal detachment. Intravitreal is a route of administration of a drug or other substance in which the
substance is delivered into the eyes. The secondary endpoint of this Phase I clinical trial is to assess retinal attachment and Virtagus
degradation at day 90 and to assess best corrected visual acuity (“BVCA”) after vitrectomy surgery. BVCA refers to the best
possible vision a person can achieve. HREC requires the primary and second endpoints to evaluate our Phase I clinical trial application.
We enrolled an aggregate number of 10 patient subjects in this trial. On November 17, 2016, we received approval from the Data and Safety
Monitoring Board for the first subject, and nine more subjects were enrolled after that. In this trial, Vitargus was injected into the
vitreous cavity of vitrectomised eyes, whose vitreous gel was removed from the vitreous cavity after vitrectomy surgery. On August 24,
2020, a full clinical study report (CSR) of the ABV-1701 Phase I clinical trial was issued. The study results showed that ABV-1701 (Vitargus)
was well-tolerated as a vitreous substitute without any apparent toxicity to ocular tissues. Further, there was no indication of an increased
overall safety risk with Vitargus. For efficacy, participants showed significant improvement in visual acuity. The optical properties
of Vitargus allowed the patients to see well and facilitated visualization of the fundus immediately following surgery. In addition, since
Vitargus was set as a stable semisolid gel adhering to the retina, it maintained its position without requiring the patient to remain
face-down following surgery.

ABV-1701, Vitargus® in vitrectomy
surgery, Phase II Study was started in the 2nd quarter of 2023. Four (4) study sites in Australia and Thailand join this multi-nation
and multi-site clinical study. The company is working on improvements to the Vitargus Product through the new batch of investigational
product.

II. Co-development
Agreement with Rgene

On May 26, 2017, American BriVision
Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”),
a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company. According to the
Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy,
ABV-17 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene
must pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation
of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not
relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to the $3.0 million, the Company is
entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and both BriVision and Rgene shall
equally share any development costs.

By June 1, 2017, the Company had delivered
all research, technical, and development data to Rgene. Since both Rgene and the Company are related parties, the Company recorded the
total amount of $3.0 million in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30,
2017. During the year ended December 31, 2017, the Company received $450,000 in cash. On December 24, 2018, the Company received the remaining
balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent
to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December
31, 2018. During the year ended December 31, 2018, the Company recognized an investment loss of $549. On December 31, 2018, the Company
determined to entirely write off this investment based on the Company’s assessment of the severity and duration of the impairment,
and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory
or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene’s ability to remain
in business. All projects that have been initiated will be managed and supported by the Company and Rgene.

9

The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, under which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.

III. Clinical
Development Service Agreement with Rgene

On June 10, 2022, the Company expanded
its co-development partnership with Rgene. BioKey entered into a Clinical Development Service Agreement with Rgene (“Service Agreement”)
to guide certain Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of
pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under
U.S. FDA IND regulatory requirements (the “Rgene Studies”).

Under the terms of the Service Agreement,
BioKey is eligible to receive payments totaling up to $3.0 million over three years with each payment amount to be determined by certain
regulatory milestones obtained during the agreement period. Through a series of transactions over the years, the Company and Rgene have
co-developed the three drug products covered by the Service Agreement and the Company acquired 26.65% of Rgene’s outstanding common
shares since 2018 through these multiple collaborative agreements.

The Company entered a convertible loan
agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department
of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion
request for the conversion was approved, but the Company was not informed by Rgene until April 2025. After the conversion, the Company
owns 37% of outstanding shares of Rgene,

Rgene has further agreed, effective July 1, 2022, to provide the Company
with a seat on Rgene’s Board of Directors until the loan is repaid in full. The Company nominated Dr. Jiang, its Chief Strategy
Officer and Director, who owns 12.8% of our common stock as of the date hereof, to occupy that seat on Rgene’s Board of Directors.
For more information about the Service Agreement and Note, please refer to the current reports on Form 8-K filed on June 21, 2022.

BLEX 404, a new drug under clinical
development covered by the Service Agreement, is extracted from the Maitake mushroom (Grifola frondosa), an edible mushroom. Its immunological
effects and safety have been demonstrated in two Phase I/II clinical studies performed at Memorial Sloan Kettering Cancer Center (MSKCC)
with breast cancer and myelodysplastic syndromes (MDS) patients.

Market Distribution Strategy

We focus primarily on developing botanical drugs
intended to diagnose, cure, mitigate, or treat human diseases. Together with our strategic partners, we plan to market, distribute and
sell our drug products internationally once those drug candidates comply with the local authorities regulations on drugs and foods. Currently,
many countries follow the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human
Use (the “ICH”) guidelines that European Medicines publish to guide the quality and safety of pharmaceutical development and
new drug commercialization in Japan, the United States and Europe. All of our drug candidates go through the United States FDA process
for new drug development and then seek regulatory approval from regulators equivalent to the FDA in the jurisdictions where we plan to
distribute those candidates.

10

Intellectual Property

The new drug candidates depend on or are the subject of the following
patents and patent applications.

No.

Status

Patent No.

Patent

Starting

Date

Patent

Expiration

Date

Patent Name

Territory

Patent

Owner(1)(2)

1

granted

DE202007003503 U1

8/23/2007

9/20/2026

Novel Polygalatenosides and use thereof as an antidepressant agent

Germany

MPITDC

2

granted

7531519

5/12/2009

9/20/2026

Novel Polygalatenosides and use thereof as an antidepressant agent

The U.S.

MPITDC

3

granted

4620652

11/20/2006

11/19/2026

Novel Polygalatenosides and use thereof as an antidepressant agent

Japan

MPITDC

4

granted

I 314453

9/21/2006

9/20/2026

Novel Polygalatenosides and use thereof as an antidepressant agent

Taiwan

MPITDC

5

granted

I389713

3/21/2013

10/13/2030

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute (3)

Taiwan

NHRI

6

granted

US 8197849 B2

6/12/2012

8/30/2030

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

The U.S.

NHRI

7

granted

AU 2011/215775 B2

4/17/2014

2/9/2031

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

Australia

NHRI

8

granted

KR 10-1428898

8/4/2014

2/9/2031

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

Korea

NHRI

9

granted

CA 2786911 (C)

10/6/2015

2/10/2031

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

Canada

NHRI

10

granted

WO2011100469 A1

N/A(4)

N/A(4)

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

PCT

NHRI

11

granted

EP 2534200

4/8/2015

2/9/2031

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy)

NHRI

12

granted

特許第 5885349號 (P5885349)

2/9/2011

2/9/2031

Cross-linked oxidized hyaluronic acid for use as a vitreous substitute

Japan

NHRI

13

granted

ZL 201180005494.7

12/24/2014

2/9/2031

Cross-linked oxidized
hyaluronic acid for use as a vitreous substitute (3)

China

NHRI

14

granted

HK1178188

3/6/2015

6/21/2030

Cross-linked oxidized
hyaluronic acid for use as a vitreous substitute (3)

Hong Kong (5)

NHRI

15

granted

US 16/936,032

9/4/2020

9/4/2040

Polygala extract for the treatment of major depressive disorder

US

BioLite

16

granted

TW I821593

11/1/2023

7/22/2040

Polygala extract for the treatment of major depressive disorder

Taiwan

BioLite

17

granted

US17/120,965

12/20/2020

12/20/2040

Polygala Extract for the Treatment of Attention Deficit Hyperactive Disorder

U.S.

BioLite

18

granted

TW 110106546

2/24/2021

2/24/2041

Polygala Extract for the Treatment of Attention Deficit Hyperactive Disorder

Taiwan

BioLite

19

granted

TW I792427

02/11/2023

07/19/2041

Storage Media For Preservation of Corneal Tissue

Taiwan

NHRI

20

granted

AU2021314052B2

04/09/2024

04/09/2041

Polygala Extract for the Treatment of Major Depressive Disorder

Australia

BioLite

11

21

applied

202180001626. 2

Polygala Extract for the Treatment of Major Depressive Disorder

China

22

applied

特願 2023502736

Polygala Extract for the Treatment of Major Depressive Disorder

Japan

23

applied

21 846 424.6

Polygala Extract for the Treatment of Major Depressive Disorder

Europe

24

applied

110106546

Polygala Extract for the Treatment of Attention-Deficient and Hyperactivity Disorder

Taiwan

25

applied

202180001615. 4

Polygala Extract for the Treatment of Attention-Deficient and Hyperactivity Disorder

China

26

applied

特願 2023536203

Polygala Extract for the Treatment of Attention-Deficient and Hyperactivity Disorder

Japan

27

applied

21 907 345.9

Polygala Extract for the Treatment of Attention-Deficient and Hyperactivity Disorder

Europe

28

applied

2021403197

Polygala Extract for the Treatment of Attention-Deficient and Hyperactivity Disorder

Australia

(1)
“MPITDC”
stands for Medical and Pharmaceutical Industry Technology and Development Center, Taiwan.

(2)
“NHRI” stands for National Health Research Institutes, Taiwan.

(3)
The patent name is translated into English and the original patent name is written as “交联氧化透明质酸作为眼球玻璃体之替代物.”

(4)
The starting date and expiration date of patents under PTC are subject to the laws of the specific participating jurisdiction where the patent application is filed. We have subsequently submitted such patent to the jurisdictions listed in No.22 herein above.

(5)
NHRI has obtained standard patent in Hong Kong based on the registration of the patent (listed as No.24 herein) granted by the State Intellectual Property Office, People’s Republic of China.

Corporate History and Structure

ABVC was incorporated under the laws of the State
of Nevada on February 6, 2002 and has three wholly-owned Subsidiaries: BriVision, BioLite Holding, Inc., and BioKey Cayman. BriVision
was incorporated in July 2015 in the State of Delaware and is in the business of developing pharmaceutical products in North America.

BioLite Holding was incorporated under the laws
of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite BVI,
Inc. (“BioLite BVI”) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite Inc. (“BioLite
Taiwan”), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new drugs
for over twelve years. Certain shareholders of BioLite Taiwan exchanged approximately 73% of equity securities in BioLite Taiwan for the
Common Stock in BioLite Holding in accordance with a share purchase/ exchange agreement (the “Share Purchase/ Exchange Agreement”).
As a result, BioLite Holding owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share
Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.

Incorporated in California on November 20, 2000,
BioKey, Inc. (“BioKey”) has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.

Upon closing of the Mergers on February 8, 2019,
BioLite and BioKey became two wholly-owned subsidiaries of ABVC.

BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception. On May 10, 2025, ABVC transferred its 100%
ownership in BioKey to BioKey Cayman. This reorganization did not have other impact to the consolidated financial statements.

12

In November 2023, the Company and one of its subsidiaries,
BioLite, Inc. (“BioLite”) each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AiBtl”,
or “AiBtl”) for the Company and BioLite’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD
(Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The license covers the Licensed Products’ clinical
trial, registration, manufacturing, supply, and distribution rights. The parties are determined to collaborate on the global development
of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration, including technology,
interoperability, and standards development. Before entering into these agreements, the Company did not have any relationship with AiBtl.
As per each of the respective agreements, each of ABVC and BioLite received 23 million shares of AiBtl stock at $10 per share, and if
certain milestones are met, each may receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million. Upon the issuance
of the shares, AiBtl became a subsidiary of ABVC.

Yun Zhi Yi Co., Ltd. (“Yun Zhi Yi”),
a Taiwanese corporation, was incorporated in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang (“Shuling”,
or “Ms. Jiang”), a director and beneficial owner of more than 10% of the ABVC’s outstanding common stock. This entity
is set up for holding land located in Puli, Tawain that AiBtl is in the process of acquiring, which land will be used for developing health
related business. Due to Taiwan’s legal restrictions prohibiting foreign entities from directly owning farmland, the parties agreed
to structure the arrangement through nominee holdings. To further secure the ownership of land, the board of AiBtl authorized Ms. Jiang
in June 2025 to temporarily hold the land title until the administrative procedures are finalized. The title was transferred to Ms. Jiang
later that month, and the Company recorded $5,794 in acquisition costs associated with the transaction. As of the date hereof, the transfer
of the land’s title to Yun Zhi Yi is currently under government review, pending completion of the title transfer registration.

The following chart illustrates the corporate structure of ABVC:

Effective March 5, 2022, the Company’s Board
for Directors approved amending the Company’s Bylaws to remove Section 2.8, which permitted cumulative voting for directors since
cumulative voting is specifically prohibited by our Articles of Incorporation. Since it is not otherwise stated in our Articles of Incorporation
or Bylaws, directors shall be elected by a plurality of the votes cast at the election, as provided in the Nevada Revised Statutes.

Effective March 14, 2024, the Company’s
Board for Directors approved amending the Company’s Bylaws to amend Section 2.8 of the Company’s Bylaws to revise the number
of shares needed to establish a quorum at shareholder meetings. The Amendment changes the quorum requirement from a majority to 33-1/3%
of the votes entitled to be cast on a matter.

13

Competition

The healthcare industry is highly competitive
and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments.
Significant competitive factors in our industry include product efficacy and safety; quality and breadth of an organization’s technology;
skill of an organization’s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals;
the average selling price of products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual
property and patent rights and their protection; and our capabilities of securing competent collaborators. Market acceptance of our current
products and product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies
or tests, (ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and distribution
capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities.

Since we are a small biopharmaceutical company
compared to other companies that we may compete against, it is our intention to license our products to much larger pharmaceutical, specialty
pharmaceutical and generic drug companies with the financial, technical and human resources to compete effectively in the markets we address.

We anticipate that our license partners will face
intense and increasing competition when and as our new drug candidates enter the markets, as advanced technologies become available and
as generic forms of currently branded products become available. Finally, the development of new treatment methods for the diseases we
are targeting could render our products non-competitive or obsolete. There can be no assurance that any of our new drug candidates will
be clinically superior or scientifically preferable to products developed or introduced by our competitors.

The following chart lists some, not all, of the
biopharmaceutical companies that research, develop, commercialize, distribute or sell drugs that are in competition with our drug candidates.

Disease

Drug Name

Pharmaceutical

Companies

Headquarters

Major Depressive Disorder

Cymbalta oral

Eli Lilly and Co., Inc.

IN

Lexapro oral

Forest Laboratories, Inc.

NJ

Pfizer Pharmaceuticals, Inc.

CT

Attention-Deficit

Adderall XR

Shire Development LLC

MA

Hyperactivity Disease

Ritalin

Novartis Pharmaceuticals Corporation

NJ

Dexedrine

Amedra Pharmaceuticals LLC

PA

Myelodysplastic

Vidaza

Celgene Corporation

NJ

Syndromes

Dacogen

Astex Pharmaceuticals, Inc.

CA

Triple Negative Breast Cancer

Avastin

Genentech, Inc.

CA

Erbitux (Cetuximab)

ImClone Systems Incorporated

NY

Pancreatic Cancer

Abraxane, Abraxis BioScience LLC

Los Angeles

CA

Novartis Pharma Stein AG

Stein

Switzerland

Vitargus for the treatments

Alcon Laboratories, Inc.

Fort Worth

TX

of Retinal Detachment or

Vitreous Hemorrhage

Arcadophta

Toulouse

France

Government Regulations

Currently, we are focusing on the research and
development of six therapeutic candidates in the fields of CNS, oncology/hematology and autoimmune, for which regulatory approval must
be received before we can commence marketing. In addition, our cGMP facility is subject to review by the FDA. Regulatory approval processes
and FDA regulations for ABVC’s current and any future product candidates are discussed below.

14

Approval Process for Pharmaceutical Products

FDA Approval Process for Pharmaceutical Products

In the U.S., pharmaceutical products are subject
to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (the “FDC Act”), and other federal and state statutes
and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling,
promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as
FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, civil penalties, and criminal prosecution. Pharmaceutical product development in the U.S. typically
involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA’s
Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated
current good manufacturing requirements, or cGMPs, including a quality system regulating manufacturing, the submission and acceptance
of an IND application, which must become effective before human clinical trials may begin in the U.S., obtaining the approval of Institutional
Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in
clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication
for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically
takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.

Pre-clinical tests generally include laboratory
evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its
potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data
and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before
human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical
practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well as international scientific
standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity
of clinical trial data.

An IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the
trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is
no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review of
an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an
independent IRB or Ethics Committee, or EC. The IRB considers, among other things, ethical factors, and the selection and safety of human
subjects. Clinical trials must be conducted in accordance with the FDA’s GCP requirements. The FDA and/or IRB may order the temporary,
or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose other sanctions
for failure to comply with requirements under the appropriate entity jurisdiction.

Clinical trials to support NDAs for marketing
approval are typically conducted in three sequential phases, but the phases may overlap.

In Phase I clinical trials, a product candidate
is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to
be used. The main purpose of the trial is to assess a product candidate’s safety and the ability of the human body to tolerate the
product candidate. Phase I clinical trials generally include less than 50 subjects or patients.

During Phase 2 trials, a product candidate is
studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended
to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential
efficacy of the product candidate for specific target diseases or medical conditions, and (iii) assess dosage tolerance and determine
the optimal dose for Phase III trials.

Phase III trials are generally undertaken to demonstrate
clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit
relationship of the product candidate. Phase III trials are generally designed to reach a specific goal or endpoint, the achievement of
which is intended to demonstrate the candidate product’s clinical efficacy and adequate information for labeling of the approved
drug.

15

The FDA has 60 days from its receipt of an NDA
to determine whether the application will be accepted for filing based on the FDA’s threshold determination that it is sufficiently
complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed
to certain performance goals in the review of NDAs. Most applications for standard review drug products are reviewed within ten months;
most applications for priority review drugs are reviewed within six months. Priority review can be applied to drugs that the FDA determines
offer major advances in treatment, or provide a treatment where no adequate therapy exists. The review process for both standard and priority
review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended
to clarify information already provided in the submission. The FDA may also refer applications for novel drug products, or drug products
which present difficult questions of safety or efficacy, to an advisory committee — typically a panel that includes clinicians
and other experts — for review, evaluation, and a recommendation as to whether the application should be approved. The
FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA,
the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility
or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMPs is satisfactory
and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

After the FDA evaluates the NDA and the manufacturing
facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If
and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval
letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA
approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh
the potential risks.

REMS can include medication guides, communication
plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training
or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval
may require substantial post-approval testing and surveillance to monitor the drug’s safety or efficacy. Once granted, product approvals
may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.

Post-Approval Regulations

Even if a product candidate receives regulatory
approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent
discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product
from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including
record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required
to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies
for compliance with cGMPs, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. ABVC
cannot be certain that ABVC or its present or future contract manufacturers or suppliers will be able to comply with cGMPs regulations
and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension
of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.

If the FDA approves one or more of our product
candidates, ABVC must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing
process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval.
The labeling, advertising, promotion, marketing and distribution of a drug must be in compliance with FDA and Federal Trade Commission,
or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry
sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement
authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing us
to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution.

Foreign Regulatory Approval

Outside of the U.S., ABVC’s ability to market
our product candidates will be contingent also upon its receiving marketing authorizations from the appropriate foreign regulatory authorities,
whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally encompasses
risks similar to those ABVC will encounter in the FDA approval process. The requirements governing conduct of clinical trials and marketing
authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and differ from those required
for FDA approval.

16

ABVC will be subject to additional regulations
in other countries in which we market, sell and import our products, including Canada. ABVC or its distributors must receive all necessary
approvals or clearance prior to marketing and/or importing our products in those markets.

Other Regulatory Matters

Manufacturing, sales, promotion and other activities
following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the
U.S., the Centers for Medicare & Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement
Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &Health Administration,
the Environmental Protection Agency and state and local governments. In the U.S., sales, marketing and scientific/educational programs
must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements
of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health
Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must
comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant
packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially
subject to federal and state consumer protection and unfair competition laws.

The distribution of pharmaceutical products is
subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended
to prevent the unauthorized sale of pharmaceutical products.

The failure to comply with regulatory requirements
subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements
can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial
suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including
government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness
of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future
products marketed by us could materially affect our business in an adverse way.

Changes in regulations, statutes or the interpretation
of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements;
(ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.

Employees

As of December 31, 2025, we, including the subsidiaries,
have 19 employees, 16 of which are full-time, located in the U.S. and Taiwan.

17